Výsledky vyhledávání - "Rebecca J, Benner"

Akademický článek

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Autor: Juliette Lambert, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Pascal Turlure, Denis Caillot, Ollivier Legrand, Xavier Thomas, Claude Gardin, Karïn Gogat-Marchant, Stephen D. Rubin, Rebecca J. Benner, Pierre Bousset, Claude Preudhomme, Sylvie Chevret, Herve Dombret, Sylvie Castaigne

Publikováno v: Haematologica, Vol 104, Iss 1 (2019)

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A

Externí odkaz: https://doaj.org/article/43cadb5fe3eb403d946e81a6eda975e0

Zobrazit plný text záznamu

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Autor: Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J. Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin

Publikováno v: Montesinos, P, Kota, V, Brandwein, J, Bousset, P, Benner, R J, Vandendries, E, Chen, Y & McMullin, M F 2023, ' A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia ', Cancer Chemotherapy and Pharmacology . https://doi.org/10.1007/s00280-023-04516-9

Purpose Gemtuzumab ozogamicin (GO) is indicated for treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). The QT interval, pharmacokinetics (PK), and immunogenicity following the fractionated GO dosing regimen have not been previously

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c04afd875b8e91197e935fe92b6aee1
https://pure.qub.ac.uk/en/publications/286069ea-b2b5-4413-90fd-3d629626116a

Zobrazit plný text záznamu

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia

Autor: Xavier Thomas, Rebecca J. Benner, Juliette Lambert, Jean-Pierre Marolleau, Karin Gogat, Emmanuel Raffoux, Ollivier Legrand, Pascal Turlure, Erik Vandendries, Sylvain Chantepie, Sylvie Castaigne, Cécile Pautas, Hervé Dombret, Lauris Gastaud

Publikováno v: Bone Marrow Transplantation
Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-020-01207-4⟩
Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-020-01207-4⟩

The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-tra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1f32a54c9fbc4bec5ea4f5f32836ec
https://pubmed.ncbi.nlm.nih.gov/33564120

Zobrazit plný text záznamu

AML-243: Gemtuzumab Ozogamicin plus Standard Chemotherapy Carries a Comparable Burden of Hospitalization Compared with Standard Chemotherapy Alone in Acute Myeloid Leukemia

Autor: Rebecca J. Benner, Verna L Welch, Slaven Sikirica, T. Alexander Russell-Smith, Paul D'Amico

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 20:S195-S196

Context For patients with de novo acute myeloid leukemia (AML), adding fractionated dosing of gemtuzumab ozogamicin (GO) to standard chemotherapy (SC) has resulted in improved outcomes. Such combination therapies may be perceived to increase the hosp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d126d6987a4446e1331a3ea77144baf
https://doi.org/10.1016/s2152-2650(20)30741-2

Zobrazit plný text záznamu

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Autor: Claude Preudhomme, Stephen D. Rubin, Emmanuel Raffoux, Sylvie Castaigne, Sylvie Chevret, Cécile Pautas, Xavier Thomas, Pascal Turlure, Pierre Bousset, Ollivier Legrand, Claude Gardin, Juliette Lambert, Rebecca J. Benner, Christine Terré, Hervé Dombret, Denis Caillot, Karïn Gogat-Marchant

Publikováno v: Haematologica
Haematologica, Ferrata Storti Foundation, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
www.haematologica.org/content/104/1/113
Haematologica, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb677892e09102942f378e3e9613adb
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01984959

Zobrazit plný text záznamu

Gemtuzumab ozogamicin for

Autor: Juliette, Lambert, Cécile, Pautas, Christine, Terré, Emmanuel, Raffoux, Pascal, Turlure, Denis, Caillot, Ollivier, Legrand, Xavier, Thomas, Claude, Gardin, Karïn, Gogat-Marchant, Stephen D, Rubin, Rebecca J, Benner, Pierre, Bousset, Claude, Preudhomme, Sylvie, Chevret, Herve, Dombret, Sylvie, Castaigne

Publikováno v: Haematologica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8a570455396af728ca5e6c37b2732b89
https://pubmed.ncbi.nlm.nih.gov/30076173

Zobrazit plný text záznamu

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

Autor: Abraham Chachoua, Cecile B. Mather, Luiz E Raez, Chandra P. Belani, Rebecca J. Benner, Peter D Eisenberg, John Nemunaitis, J Daniel Cuevas, Sandra J. Meech

Publikováno v: Cancer Biology & Therapy. 14:557-563

This phase 2 study assessed PF-3512676 plus erlotinib in patients with epidermal growth factor receptor-positive advanced non-small cell lung cancer after prior chemotherapy failure. Patients were randomized 1:1 to PF-3512676 (0.20 mg/kg injected sub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccdd744293f7410329060e41ff341710
https://doi.org/10.4161/cbt.24598

Zobrazit plný text záznamu

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

Autor: Petr Zatloukal, Maria Blasinska-Morawiec, Sandra J. Meech, Jacek Jassem, Nick Thatcher, Christian Manegold, Rebecca J. Benner, N. van Zandwijk, Eng Huat Tan, A. Ingrosso, Piotr Serwatowski, Maciej Krzakowski, David Robert John Readett, Aleksandra Szczesna, J. S.-K. Au

Publikováno v: Annals of Oncology. 23:72-77

Background This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). Patients and methods Chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4b644b42c5fb46097d8cebcd58d6a1
https://doi.org/10.1093/annonc/mdr030

Zobrazit plný text záznamu

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Autor: Juliette Lambert, Rebecca J. Benner, Erik Vandendries, Sylvie Castaigne, Cécile Pautas, Emmanuel Raffoux, Hervé Dombret, Karin Gogat, Ollivier Legrand

Publikováno v: Blood. 132:28-28

Introduction: The randomized phase 3 ALFA-0701 study demonstrated improved outcomes with the addition of gemtuzumab ozogamicin (GO) to standard 7+3 chemotherapy in patients with de novo acute myeloid leukemia (AML; Castaigne et al, Lancet 2012). 85 o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b14290740c0baf691f8525e32e7b4af4
https://doi.org/10.1182/blood-2018-99-111251

Zobrazit plný text záznamu

Clinical Pharmacokinetics and Gastrointestinal Tolerability of a Novel Extended-Release Microsphere Formulation of Azithromycin

Autor: Amarnath Sharma, Lisa J. Benincosa, Rebecca J. Benner, Robert R. LaBadie, Ping Liu, Jeannine M Fisher, Charles Xie, Jeanne D. Breen, Ridia Chandra

Publikováno v: Clinical Pharmacokinetics. 46:247-259

A novel oral, extended-release, microsphere formulation of azithromycin (AZSR) was developed to improve the gastrointestinal tolerability profile while allowing administration of an entire treatment course of azithromycin in a single dose. Several ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d8c62be67806044bcb7189da87913b
https://doi.org/10.2165/00003088-200746030-00005

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání